Washington loves a victory lap before the race even starts.
Every few years, a White House administration steps up to the podium, points a finger at pharmaceutical executives, and announces a bold new initiative to slash Medicaid drug prices. The press eats it up. Policy wonks nod approvingly. Taxpayers assume relief is on the way.
They are wrong. Every single time.
The mainstream coverage surrounding Trump’s push to lower Medicaid prescription costs relies on a fatal misunderstanding of how drug pricing actually works in the United States. Pundits treat Medicaid like a standard retail pharmacy customer getting gouged at the register. They assume that if the government just negotiates harder or ties prices to foreign benchmarks, the bill drops.
That is fantasy economics.
Medicaid already gets the lowest drug prices in the American healthcare system by federal statute. Trying to squeeze blood from a stone that has already been crushed by mandatory rebates does not lower healthcare spending. It simply triggers a shell game where pharmaceutical manufacturers shift costs to private insurance, restrict access to lifesaving therapies, and quietly pocket the difference through accounting tricks.
If you want to understand why this program is theatrical politics masquerading as reform, you have to look under the hood of the Medicaid Drug Rebate Program.
The Myth of the Overpaying Medicaid System
Let’s kill the biggest lie first. The public believes Medicaid is getting ripped off by Big Pharma.
In reality, Medicaid operates under a strict statutory pricing floor established back in 1990. Under the Medicaid Drug Rebate Program (MDRP), manufacturers must give state Medicaid programs a mandatory baseline rebate of 23.1 percent off the Average Manufacturer Price (AMP) for brand-name drugs, or the difference between AMP and the "best price" offered to virtually any other commercial purchaser in the country—whichever is greater.
Read that again. Medicaid is legally guaranteed the absolute lowest price in the entire commercial market.
On top of that, manufacturers are penalized if they raise prices faster than inflation. Because of these inflationary penalties, the net cost of many older brand-name drugs in Medicaid has literally dropped to zero. In some cases, pharmaceutical companies actually pay states to dispense their drugs because the statutory rebates exceed the list price.
I have sat in boardrooms with market access executives watching them model these exact numbers. They do not lose sleep over Medicaid list prices. They treat Medicaid as a statutory write-off and build their entire commercial pricing architecture around protecting their "Best Price" metric.
When a political administration promotes a new program to "reduce Medicaid drug prices," they are attacking a problem that was largely solved thirty years ago. The real crisis in Medicaid pharmacy spending isn't the unit price of standard pills. It is the explosion of ultra-expensive specialty biologics and gene therapies that bypass traditional rebate structures, combined with the middlemen skimming billions off the top.
The Best Price Trap Nobody Talks About
Here is the counter-intuitive reality that breaks the brains of most healthcare journalists: pushing Medicaid prices even lower actually drives prices up for everyone else.
Because Medicaid demands the "Best Price" available anywhere in the private sector, pharmaceutical companies are terrified of offering deep discounts to commercial health plans, employers, or hospital systems. If a drugmaker gives a steep discount to a commercial insurer to help working families afford a medication, federal law forces them to hand that exact same discount to every single Medicaid program across fifty states.
Imagine a scenario where a manufacturer develops a breakthrough treatment for a rare disease, priced at $100,000 a year. A large private employer wants to negotiate a 50 percent discount so their workers can access it without going bankrupt. The drugmaker refuses. Why? Because triggering a 50 percent "Best Price" resets their mandatory Medicaid rebate floor nationwide, obliterating their profit margins overnight.
When Trump’s programs—or any administration’s initiatives—attempt to force even steeper concessions on Medicaid, manufacturers respond in one of two ways:
- They inflate launch prices. If the government is going to demand a 50 percent or 70 percent discount out of the gate, companies simply double the starting list price to protect their net revenue.
- They starve the commercial market of discounts. Employers and privately insured patients end up subsidizing the statutory discounts handed to the government.
You aren't watching a reduction in healthcare costs. You are watching a massive, hidden tax transferred directly onto the premiums and deductibles of working Americans.
The Most Favored Nation Illusion
A centerpiece of Trump’s pricing philosophy has always been international reference pricing—often pitched as a "Most Favored Nation" model. The logic sounds seductive on a campaign stage. Why should an American Medicaid program pay $500 for an injection that costs $80 in Germany or France? Just mandate that Medicaid pays the lowest price paid by any developed foreign nation.
On paper, it looks like a knockout punch. In practice, it is economic malpractice.
Foreign governments achieve those low prices through single-payer rationing. Agencies like the UK’s National Institute for Health and Care Excellence (NICE) use strict cost-effectiveness thresholds—specifically Quality-Adjusted Life Years (QALYs)—to simply deny coverage for expensive new drugs. If a cancer drug costs too much per month of life extended, British patients don't get it. Period.
American law explicitly prohibits Medicaid from using QALYs to deny access, and federal mandates require state Medicaid programs to cover virtually every FDA-approved drug made by participating manufacturers.
You cannot import European prices without importing European rationing.
If you force drugmakers to sell to Medicaid at German prices while legally obligating Medicaid to buy every drug on the market, manufacturers will simply delay launching new drugs in Europe, or pull out of international markets altogether to protect their US pricing floor. We have already seen the Congressional Budget Office (CBO) and independent health economists at organizations like the RAND Corporation point out that aggressive reference pricing leads to launch delays and reduced R&D investment in high-risk therapeutic areas.
Even worse, foreign prices are fake. European governments negotiate confidential rebates behind closed doors. The "list price" in France is an illusion, meaning any US program benchmarking against foreign data is anchoring itself to fabricated numbers.
The Real Villains Are Hiding in Plain Sight
If you want to know why state Medicaid pharmacy budgets are bleeding cash, stop looking at the pharmaceutical factories and start looking at the Pharmacy Benefit Managers (PBMs).
PBMs are the corporate middlemen hired by state Medicaid agencies and managed care organizations to process prescriptions and negotiate rebates. Three massive conglomerates—CVS Caremark, Express Scripts, and OptumRx—control roughly 80 percent of the entire US prescription drug market.
For years, these middlemen mastered a predatory practice known as spread pricing.
Here is how the scam works: A PBM charges a state Medicaid program $100 for a generic drug. They then turn around and reimburse the local independent pharmacy $15 for dispensing that exact same pill. The PBM pockets the $85 difference—the "spread"—and reports it as administrative revenue.
Even as states have cracked down on spread pricing, PBMs have simply mutated their fee structures. They now extract massive "administrative fees," "data fees," and "rebate aggregation fees" that are tied directly to the list price of a drug.
Think about the perverse incentive that creates. A PBM makes more money when a drug has a high list price and a massive rebate than when a drug has a low, transparent net price. Consequently, PBMs actively block lower-cost generics and biosimilars from Medicaid formularies because cheap drugs don't generate juicy rebate fees.
Let's be honest about the numbers. Investigations by state auditors in Ohio, Kentucky, and New York uncovered hundreds of millions of dollars in hidden PBM spread pricing within their Medicaid programs alone. While politicians hold press conferences bragging about squeezing drug manufacturers, the middlemen are quietly siphoning billions out of the back door.
Answering the Questions You Should Actually Be Asking
When headlines drop about presidential drug pricing plans, people rush to search engines with the wrong questions. Let’s dismantle the conventional wisdom right now.
Will this actually lower my out-of-pocket costs at the pharmacy counter?
No. If you are on Medicaid, your copays are already capped at nominal amounts—usually between $1 and $4 per prescription, or zero in many states. You will not feel a penny of difference at the register. If you have private insurance through your employer, this could actually increase your out-of-pocket costs, because your coinsurance is calculated off the inflated list price that manufacturers use to offset government rebates.
Why doesn't the government just cap the price of all drugs?
Because price controls destroy supply. Every time a government imposes rigid price ceilings on a complex manufacturing sector, shortages follow. We already see this in the generic sterile injectable market—drugs like basic chemotherapy agents and hospital saline—where razor-thin profit margins driven by aggressive purchasing consolidation have caused catastrophic nationwide shortages. Push margins to zero, and manufacturers shut down production lines.
Are state Medicaid programs actually running out of money because of drug prices?
State budgets are certainly strained, but pharmacy spending still accounts for less than 10 percent of total net Medicaid expenditures after rebates are factored in, according to data from the Medicaid and CHIP Payment and Access Commission (MACPAC). The real budget-busters in Medicaid are long-term care for the elderly and disabled, hospital inpatient services, and chronic disease management. Focusing exclusively on pill prices is like trying to fix a sinking ship by polishing the brass railings.
How to Actually Fix Medicaid Drug Spending
If policymakers wanted to stop the bleeding instead of chasing headlines, they would abandon federal pricing gimmicks and execute four structural reforms immediately.
1. Abolish the "Best Price" Rule Completely
Eliminate the statutory link between Medicaid rebates and commercial discounts. Replace it with a flat, predictable, transparent percentage discount off the net price. The moment you remove the "Best Price" penalty, pharmaceutical companies can finally offer massive, targeted discounts to private employers, cash-paying patients, and value-based insurance plans without blowing up their government contracts.
2. Ban Rebates and Mandate Point-of-Sale Net Pricing
Stop allowing PBMs and insurers to play games with inflated list prices and backend rebates. Mandate that all drug transactions in Medicaid—and across the broader market—occur at the true net price at the pharmacy counter. If a drug costs $40 after discounts, the invoice should say $40. Transparency kills spread pricing overnight.
3. Build Separate Risk Pools for Million-Dollar Gene Therapies
Medicaid was designed in 1965 to cover routine doctor visits and basic medications, not one-time $3 million cellular therapies for sickle cell disease or spinal muscular atrophy. When a single patient requires a multi-million-dollar cure, it can bankrupt a small state’s quarterly pharmacy budget. Instead of demanding artificial price cuts that discourage biotech investment, the federal government should create a dedicated, federally funded reinsurance pool specifically for ultra-high-cost curative therapies.
4. Enforce Radical PBM Fiduciary Standards
Force every PBM contracting with a state Medicaid managed care plan to act as a strict legal fiduciary. That means they must pass 100 percent of all rebates, fees, and manufacturer payments directly back to the state, earning only a flat, transparent per-member-per-month administrative fee. No percentages. No spread. No hidden offshore rebate aggregators.
The Trade-Off Nobody Wants to Admit
Let’s be brutally honest about the downside of my own approach.
If you abolish the "Best Price" rule and shift to flat statutory rebates, some state Medicaid programs might pay slightly more in the short term for certain heavily rebated legacy brand-name drugs. Furthermore, creating a federal reinsurance pool for gene therapies requires upfront taxpayer appropriations rather than hiding the cost inside complex manufacturer rebate formulas.
Politicians hate upfront honesty. They prefer accounting tricks that let them claim massive "savings" on a ten-year Congressional budget score while quietly shifting the financial burden onto private sector workers and local pharmacies.
Stop Falling for Political Theater
Drug pricing in America is not broken because politicians haven't shouted loud enough at pharmaceutical CEOs. It is broken because the statutory architecture of Medicaid rewards list-price inflation, protects predatory middlemen, and punishes companies for offering genuine discounts in the private market.
Trump’s program—just like the programs pushed by his predecessors—treats the symptoms while feeding the disease. Until Washington dismantles the rebate cartel and decouples Medicaid from private-market pricing, every new "historic" drug plan is just another press release waiting to fail.
Ignore the podium. Watch the net prices.
